

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
WORLD'S FIRST SERUM-FREE ITERATIVE RABIES VACCINE
SUCCESSFULLY PASSED ON-SITE INSPECTION FOR REGISTRATION

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

As per the “Notice from the Center for Drug Evaluation Regarding the On-Site Inspection for the Registration for the Serum-Free Iterative Rabies Vaccine” issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, based on technical review requirements, an on-site inspection for registration has been organized and conducted for the serum-free iterative rabies vaccine (Acceptance No.: CXSS2500044) registered and submitted by AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (hereinafter referred to as “**AIM Rongyu**”), a wholly-owned subsidiary of the Group, for the world’s first self-developed serum-free iterative rabies vaccine. To date, AIM Rongyu has successfully passed the on-site inspection of drug clinical trials and the on-site inspection for drug registration and production.

According to the results of the Phase III clinical trials, which have completed unblinding, the Group’s serum-free iterative rabies vaccine has demonstrated good safety, immunogenicity and immune persistence, fully meeting the pre-defined evaluation criteria for the clinical trials. Previously, AIM Rongyu has obtained the corresponding production license for the serum-free iterative rabies vaccine. At present, there is no serum-free rabies vaccine that has been approved for launch in the global market. After the launch of this product by the Group, it is expected to fill the market gap, marking a major technological breakthrough for the Group and further cementing the Group’s leading position in the global rabies vaccine industry.

Rabies is the disease with the highest fatality rate worldwide, with nearly 100% mortality after symptom onset. Currently, there is a lack of effective treatment for rabies in clinical practice. Therefore, post-exposure prevention is crucial, and the main preventive measure is vaccination against human rabies. There are two kinds of rabies vaccines, namely the serum-containing rabies vaccine and the serum-free rabies vaccine. However, no serum-free rabies vaccine has been registered or marketed globally yet. The mainstream Vero cell rabies vaccine and human diploid rabies vaccine currently available in the market are serum-containing rabies vaccines.

Completely unlike the traditional Vero cell rabies vaccine and human diploid rabies vaccine, the serum-free iterative rabies vaccine developed by the Group is an iterative upgraded product. Animal serum residues in vaccine products is one of the important factors leading to adverse reactions such as allergies in vaccinated populations, and the serum-free iterative rabies vaccine developed by the Group does not contain animal serum, which significantly improves safety and reduces the incidence of adverse reactions.

China is the largest rabies vaccine market globally. According to China Insights Consultancy, driven by product innovation and iteration, and increased accessibility to rabies vaccines, the market size is projected to reach RMB14.8 billion by 2030. In accordance with the “Guidelines for the Prevention and Treatment of Rabies Exposure (2023 Edition)” (《狂犬病暴露預防處置工作規範》(2023年版)) issued by the National Disease Control and Prevention Administration and the National Health Commission, rabies prevention and treatment clinics should be equipped with at least two different types of rabies vaccines. Leveraging its iterative technological advantages, the Group’s product is expected to become the first choice for vaccination institutions.

As the world’s second largest supplier of rabies vaccines, the Group is committed to leading the in-depth technology iteration and upgrading of rabies vaccines globally. It has completed the construction of a serum-free iterative rabies vaccine workshop that meets international standards, as well as the commercial-scale validation production, and is now capable of producing this product on a large scale. Once the product is approved, it can be rapidly launched into the market. Upon regulatory approval and commercialisation, this vaccine is expected to deliver a significant boost to the Group’s results.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, February 5, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO as non-executive director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.